Review Article | Open Access
Chen Mao, Vincent C. H. Chung, Jin-Qiu Yuan, Yuan-Yuan Yu, Zu-Yao Yang, Xin-Yin Wu, Jin-Ling Tang, "Evaluation of the Add-On Effect of Chinese Patent Medicine for Patients with Stable or Unstable Angina: A Systematic Review and Meta-Analysis", Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 673193, 15 pages, 2013. https://doi.org/10.1155/2013/673193
Evaluation of the Add-On Effect of Chinese Patent Medicine for Patients with Stable or Unstable Angina: A Systematic Review and Meta-Analysis
Chinese herbal medicine (CHM) has been widely used as an adjunct to western medicine in treating angina in China. We carried out this systematic review to evaluate the effectiveness of CHM on top of western medicine for angina. This meta-analysis included 46 randomized control trials with 4212 patients. For trials that included stable angina patients, the CHM group had significant lower incidence of total heart events (relative risk , 95% confidence interval (CI) 0.33–0.78), myocardial infarction (, 95% CI 0.14–0.72), heart failure (, 95% CI 0.15–0.91), and angina (, 95% CI 0.30–0.71) than that of control group. For trials that included unstable angina patients, CHM led to significantly lower occurrence of total heart events (, 95% CI 0.32–0.66), myocardial infarction (, 95% CI 0.26–0.54), and angina (, 95%CI 0.26–0.51). Likewise, for trials that included stable or unstable angina patients, the rates of myocardial infarction (, 95% CI 0.17–0.68) and angina (, 95% CI 0.30–0.70) in CHM group were significantly lower than that in control group. In conclusion, CHM is very likely to be able to improve the survival of angina patients who are already receiving western medicine.
Angina is pain or constricting discomfort that typically occurs in the front of the chest and is brought on by physical exertion or emotional stress . It is the main symptomatic manifestation of myocardial ischemia, caused by an imbalance between myocardial blood supply and oxygen demand [1, 2]. The prevalence of angina in the population appears to increase in the past decades . A meta-analysis of data from 31 countries indicated the population weighted prevalence was 6.7% in woman and 5.7% in man . Angina is a common initial presentation of coronary disease , and it may exert a major impact on quality of life, ability to work, and costs to society [6, 7].
Angina is clinically classified into stable angina (SA) and unstable angina (UA), and treatment strategy is different between them. SA is a chronic medical condition and the aim of management for it is to abolish or minimize symptoms, improve quality of life, and decrease long-term morbidity and mortality  while UA is an acute coronary syndrome, which should be treated as an emergency . The current antiangina medical management includes pharmacological strategies, revascularization strategies, and lifestyle interventions. Chinese herbal medicine (CHM) is also widely used for treating angina in China .
Because angina is a life-threatening event and very effective western medicine treatments are available, CHM is usually used in addition to baseline treatment with western medicine. Common CHM prescribed for treating angina includes Tongxinluo capsules, Fufangdanshen dripping pills, Shengmai capsules, and Shexiangbaoxin tablets. Tongxinluo capsules mainly take effect by dilating coronary arteries, increasing blood vessel perfusion flow, and strengthening cardiac contractility [10, 11]. Fufangdanshen dripping pills may alleviate angina via the antimyocardial ischemia and antiatherosclerotic effect [12, 13]. Likewise, not only can Shengmai capsules raise coronary blood flow, it may also improve the tissue tolerance to oxygen privation of cardiac muscle . Apart from expanding blood vessel and increasing crown arteries current capacity, Shexiangbaoxin tablets may also alleviate arteriosclerosis and steady plague . However, there is still a knowledge gap to clearly establish evidence that CHM is effective in improving the outcomes of angina patients. We therefore performed this systematic review of randomized controlled trials (RCT) to evaluate the add-on effect of CHM in angina patients.
2. Materials and Methods
2.1. Inclusion Criteria
Studies are eligible if (1) RCTs which compared CHM + western medicine versus western medicine, or compared CHM versus no treatment/placebo; (2) the participants were patients with stable or unstable angina (diagnosed by typical angina chest pain, and ischemic ST-segment depression by electrocardiography); (3) the intervention may be any preparations containing at least one herb that is included in the latest version of the Chinese Pharmacopeia; (4) the follow-up time should be at least 7 days. The primary outcome of this study is mortality (death from myocardial infarction (MI) and other causes). The secondary outcomes include recurrent MI, heart failure, quality of life, use of revascularization, deterioration or improvement in symptoms of angina, and adverse events. Trials were eligible if one of the hard outcomes (mortality, recurrent MI, or heart failure) was reported.
2.2. The Literature Search
We searched CENTRAL, MEDLINE, EMBASE, CINAHL, AMED, Chinese Biomedical Database (CBM), Chinese Medical Current Contents (CMCC), and Traditional Chinese Medical Literature Analysis and Retrieval System (TCMLARS) since their inception to July 2010 (Figure 1). There was no limitation on language or publication status. The search strategy included the following key words: “Chinese herbal,” “traditional Chinese medicine,” “herb,” “angina,” “stenocardia,” “clinical trials,” and “randomized controlled trial.” The reference lists of relevant trials and review articles, abstracts from major relevant conferences, and relevant trials registers were checked for additional studies.
2.3. Selection of Studies
Study eligibility was independently determined by two authors. All the citations were inputted into reference management software Endnote, and the duplicates were removed. The authors then evaluated the eligibility of remaining studies by examining the titles, abstracts, and full articles progressively. Discrepancies were resolved by discussion.
2.4. Data Extraction and Quality Assessment
Data were extracted independently by two authors using a standard form. Data extracted include (1) general information (e.g., title, authors, reference, language, year of publication, and setting); (2) trial characteristics related to methodological quality (e.g., design, duration of followup, sequence generation, allocation sequence concealment, and blinding); (3) intervention and comparison (dose, route, and timing); (4) patients (e.g., baseline characteristics and diagnostic criteria); (5) outcomes (e.g., estimates, standard error, and value). Discrepancies were resolved by discussion. The authors of original studies were consulted for missing information where necessary.
The methodological quality of included randomized trials was assessed and reported by the Cochrane Collaboration’s tool to assess the risk of bias . The methodological quality assessed included: (1) sequence generation, (2) allocation sequence concealment, (3) blinding, (4) incomplete outcome data, (5) selective outcome reporting, and (6) other potential sources of bias.
2.5. Data Analysis
All analyses were conducted using the Review Manager software compiled by the Cochrane Collaboration . Dichotomous outcomes were expressed as relative risk . 95% confidence intervals (CIs) were calculated for all estimates. Tests for heterogeneity were performed with chi-squared test at a significance level of . statistic was calculated to estimate variation across studies. We regarded as an indicator of low heterogeneity level, 25–50% as moderate level, and >50% as high level. The estimates were pooled with a fixed-effect model if there was no significant heterogeneity. Whenever a significant heterogeneity presented, a random-effect model was used to pool the results. We intended to explore the potential sources of heterogeneity by subgroup analysis and metaregression if the number of trials was sufficient. We assessed the publication bias by funnel plot, and adjustment was made to reduce the effect of publication bias in the estimate of effectiveness.
3.1. The Literature Search and Study Characteristics
Figure 1 showed the study selection in this study. Our search in bibliographic databases yielded 15866 citations, of which 2660 were classified as potentially relevant and were subjected to full text assessment. Finally, a total of 46 studies were included [18–63], of which 9 studies included patients with SA [18–26], 31 studies included patients with UA [27–57], and 6 studies included patients with SA or UA [58–63]. This systematic review totally included 4212 patient, with 2141 patients receiving the combination of CHM and western medicine and 2071 patients receiving western medicine alone. The duration of treatment and followup ranged from 1 day to 48 days, and 7 months to 36 months, respectively. Table 1 demonstrated the characteristics of included studies.
|SA: stable angina; UA: unstable angina; WM: west medicine; NR: not reported.|
3.2. Risk of Bias
Among included studies, only 6 trials concealed allocation sequence, two studies did not conceal the allocation sequence generated, and the rest studies were unclear. As to randomization, two studies had high risk of bias, and the rest studies had either low or uncertain risk of bias. All the included studies had low risk of bias except one study that had high risk of bias for selective outcome reporting. The details are shown in Table 2 and Figure 2.
3.3. Add-On Effect of Chinese Herbal Medicine in Patients with SA
For trials that only included SA patients, we analyzed the following outcomes: total heart events (3 trials), MI (7 trials), cardiac arrhythmia (2 trials), heart failure (3 trials), angina (6 trials), and death (2 trials). All pooled results showed homogeneity (). Though the SA patients in CHM group had a lower death rate (1.74%) than SA patients in control group (5.22%), the difference was not statistically significant (). Twenty-three out of 150 SA patients who were treated with the combination of CHM with western medicine got total heart events, with an incidence rate of 15.33%, which was significantly lower (, 95% CI 0.33–0.78; ) than that of SA patients who were treated with western medicine alone (30.61%). Compared with western medicine alone, the combination of CHM with western medicine significantly reduced the occurrence of myocardial infarction, from 6.67% to 1.85, with the pooled equal to 0.32 (95% CI 0.14–0.72, ). The incidences of heart failure (, 95% CI 0.15–0.91; ), cardiac arrhythmia (, 95% CI 0.13–0.57; ), and angina (, 95% CI 0.30–0.71; ) were also significantly lower in SA patients who were treated with the combination of CHM with western medicine than that of patients treated with western medicine alone. There were only one study that explored the difference of difference on the outcomes of fatal events, sudden cardiac death, and adverse events such as bleeding and stomach discomfort between patients in CHM group and patients in control group, none of them were different between two groups. Visual inspection of the funnel plots revealed no asymmetry except the meta-analysis of the occurrence of angina. Details of statistical results can be found in Table 3 and Figures 3, 4, 5, 6, and 7.
|CHM: chinese herbal medicine; RR: risk ratio; CI: confidence interval; PCI: percutaneous transluminal coronary intervention.|
3.4. Add-On Effect of Chinese Herbal Medicine in Patients with UA
For trials that only included UA patients, we analyzed the following outcomes: total heart events (7 trials), death (1 trial), MI (19 trials), cardiac arrhythmia (1 trial), heart failure (2 trials), angina (12 trials), need for cardiac surgery (2 trials), and need for PCI (3 trials). All pooled results showed homogeneity. There are 337 patients in CHM group, of whom 36 patients developed total heart events (10.68%), while 78 out of 333 patients (23.42%) in the control group occurred total heart events. Patients in CHM group had a significant lower incidence of total heart events than patients in the control group, with a pooled equal to 0.46 (95% CI 0.32–0.66, ). Compared with western medicine alone, the combination of CHM with western medicine significantly reduced the occurrence of myocardial infarction, from 12.42% in control group to 4.26% in CHM group, with a pooled of 0.37 (95% CI 0.26–0.54, ). Patients in the CHM group had significant lower heart events (, 95% CI 0.32–0.66; ), myocardial infarction (, 95% CI 0.26–0.54; ), angina (, 95% CI 0.26–0.51; ), and sudden cardiac death (, 95% CI 0.06–0.84; ) than patients in control group. Pooled result showed no significant difference on death (, 95% CI 0.01–3.84; ), heart failures (, 95% CI 0.15–1.09; ) and fatal events (, 95% CI 0.07–1.62; ) between groups. Two studies presented the data on the adverse events on the treatment, and there is no significant difference on bleeding and stomach discomfort between groups. Visual inspection of funnel plots suggesting there’s no publication bias. Details of statistical results can be found in Table 3 and Figures 8, 9, 10, 11 and 12.
3.5. Add-On Effect of Chinese Herbal Medicine in Patients with SA and UA
For trials including patients with diagnosis of either SA or UA, we analyzed the following outcomes: total heart events (1 trial), MI (4 trials), cardiac arrhythmia (1 trial), heart failure (2 trials), angina (4 trials), need for cardiac surgery (1 trial), and death (2 trials). All pooled results showed homogeneity. Total death rate in CHM group was 3.47% (6/173), compared with 5.44% (11/202) for the control group. The result showed that patients treated with CHM did not have a significant lower death rate than no-CHM treatment patients group, with a pooled of 0.58 (95% CI 0.23–1.48; ). There was no evidence of statistical heterogeneity across the studies using the test (, ). Meta-analysis of trials comparing the effect of CHM with no CHM treatment in patients with either SA or UA showed that the myocardial infarction rate was 3.13% (10/320) and 8.91% (31/348) in CHM treatment group and control group, respectively, with a pooled of 0.34 (95% CI 0.17–0.68; ). There was enough evidence to illustrate that patients with CHM treatment had a significant lower myocardial infarction rate than the control group. No evidence of statistical heterogeneity across the studies was identified using the test (, ). Meta-analysis showed that patients with CHM treatment had a significant lower angina rate than no CHM treatment group, with a pooled of 0.46 (95% CI 0.30–0.70; ). There was no evidence of statistical heterogeneity (, ). Visual inspection of funnel plots suggesting no publication bias. Details of statistical results can be found in Table 3 and Figures 13, 14, 15 and 16.
This systematic review synthesized evidence from 4212 patients in 46 RCTs. The main findings of this systematic review are as follows. (1) The combination of CHM with western medicine may significantly reduce the occurrence of total heart events, MI, cardiac arrhythmia, heart failure, and angina compared with western medicine alone in patients with SA. (2) For patients with UA, the combination therapy is superior to western medicine alone on total heart events, myocardial infarction, angina, and sudden cardiac death. But there is no significant difference on the incidence of death, cardiac arrhythmia, hart failure, fatal events, cardiac surgery, and percutaneous coronary intervention. (3) For patients with SA or UA, the combination therapy may lead to significant lower occurrence of myocardial infarction, heart failure, and angina as compared with western medicine monotherapy, but no significant differences were indentified on the incidence of total heart events, death, cardiac arrhythmia, fatal events, sudden cardiac death, cardiac operation, bleeding, and stomach discomfort.
Apart from this study, the add-on benefits of CHM on top in western medicine treatment in angina patients were also studied in some other systematic reviews . It was suggested that Danshen preparation [65, 66], Dengzhanhua injection , Tongxinluo capsule [68, 69], Shuxuetong , Ginkgo extract [71, 72], and Compound salvia pellet [73, 74] would be beneficial for angina patients. These systematic reviews usually only focused on one type of CHM [15, 65–67, 69–73], included only a limited number of original studies [65, 67, 70], and did not receive update for a long time [66, 67, 69], and their conclusions may therefore be influenced.
The overall risk of bias of included studies was moderate. Inadequacy in reporting methods for randomization and allocation concealment is a major problem among most included RCTs, which may lead to selection bias in our study . The lack of blinding is another problem in most included trials; however, the impact on conclusion was less critical as we focused on objective outcomes. Visual inspection of funnel plots indicated no symmetry on most outcomes, except for the meta-analysis of angina in patients with SA. We therefore believe publication bias is unlikely to be a serious threat to the estimates.
Apart from the limitations on the quality of included studies, the estimates of some outcomes, such as the incidence of fatal events, sudden cardiac death, and bleeding in patients with UA are also limited by relatively small sample size. For these outcomes, only one study with less than 100 patients was included in meta-analysis, and the precision of estimates was therefore influenced .
To the best of our knowledge, this is the most comprehensive assessment of add-on effect of CHM in patients with angina. We employed a contemporaneous search strategy in both international and Chinese databases to ensure most studies were included. This enabled us to locate a much higher number of studies compared to other existing reviews on this topic. Additionally, the study selection, data extraction, and quality assessment in this study were independently carried out by two authors to ensure high validity.
This study has important implication for clinical practice and CHM research. For practitioners, this systematic review demonstrated consistent, add-on benefits of using CHM on top in western medicine treatment for preventing all-cause and cardiac mortality amongst angina patients. However, this conclusion was drawn from moderate or low quality trials and the estimates on some outcomes were based on limited number of patients. Large scale, rigorously designed RCTs are still wanted to confirm these conclusions.
Conflict of Interests
All authors declare that they have no conflict of interests.
Chen Mao and Vincent C. H. Chung are the cofirst authors of this paper.
This study is funded by the Chinese Medicine Department, Hong Kong Hospital Authority (CUHK Project code: 7050098).
- R. A. Henderson and N. O'Flynn, “Management of stable angina: summary of NICE guidance,” Heart, vol. 98, no. 6, pp. 500–507, 2012.
- H. H. Gray, R. A. Henderson, M. A. de Belder, S. R. Underwood, and A. J. Camm, “Early management of unstable angina and non-ST-segment elevation myocardial infarction: summary of NICE guidance,” Heart, vol. 96, no. 20, pp. 1662–1668, 2010.
- F. C. Lampe, R. W. Morris, M. Walker, A. Gerald Shaper, and P. H. Whincup, “Trends in rates of different forms of diagnosed coronary heart disease, 1978 to 2000: prospective, population based study of British men,” British Medical Journal, vol. 330, no. 7499, pp. 1046–1049, 2005.
- H. Hemingway, C. Langenberg, J. Damant, C. Frost, K. Pyörälä, and E. Barrett-Connor, “Prevalence of angina in women versus men: a systematic review and meta-analysis of international variations across 31 countries,” Circulation, vol. 117, no. 12, pp. 1526–1536, 2008.
- N. Sekhri, G. S. Feder, C. Junghans, H. Hemingway, and A. D. Timmis, “How effective are rapid access chest pain clinics? Prognosis of incident angina and non-cardiac cnest pain in 8762 consecutive patients,” Heart, vol. 93, no. 4, pp. 458–463, 2007.
- H. S. Javitz, M. M. Ward, J. B. Watson, and M. Jaana, “Cost of illness of chronic angina,” The American Journal of Managed Care, vol. 10, supplement, no. 11, pp. S358–S369, 2004.
- J. A. Spertus, P. Jones, M. McDonell, V. Fan, and S. D. Fihn, “Health status predicts long-term outcome in outpatients with coronary disease,” Circulation, vol. 106, no. 1, pp. 43–49, 2002.
- R. S. Wright, J. L. Anderson, and C. D. Adams, “2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Journal of the American College of Cardiology, vol. 60, no. 7, pp. 645–681, 2012.
- J.-L. Tang, B.-Y. Liu, and K.-W. Ma, “Traditional Chinese medicine,” The Lancet, vol. 372, no. 9654, pp. 1938–1940, 2008.
- H.-J. Wang, Y.-W. Huang, and J. Sun, “Effect of tongxinluo capsule on function of vascular endothelium in patients with unstable angina pectoris,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 23, no. 8, pp. 587–589, 2003.
- C. Chen, “Effect of Scolopendra extract in experiment onrabbit heart,” Chinese Medicine Pharmacology and Clinical Practice, vol. 1, no. 1, pp. 124–125, 1985.
- J. Zhai, “The clinical control study of Fufangdanshen dropping pills in the treatment of coronary artery disease Angina pectoris,” Chinese Primary Health Care, vol. 23, no. 7, pp. 92–93, 2009.
- S. He, J. Chen, and L. Zhu, “The Effect of Fufangdanshen on hemorheology in patients with Stable Angina,” Clinical Journal of Hemorrhage, vol. 18, no. 1, pp. 92–95, 2008.
- X. H. Liu, “Shengmai capsules for the treatment of unstable angina,” China Medical Herald, vol. 6, no. 34, pp. 147–148, 2009.
- D. Zhao, “Clinical evaluation of treatment of unstable Angina pectoris (UAP) by metoprolol succinate sunstanedrelease tablets combined with Shexiangbaoxin pill,” China Practical Medicine, vol. 5, no. 23, pp. 82–83, 2010.
- J. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions Version 5. 1. 0, The Cochrane Collaboration, 2011, http://handbook.cochrane.org/.
- D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” British Medical Journal, vol. 339, Article ID b2535, 2009.
- H. Qi, J. G. Liu, J. Du, and F. Wang, “Evaluating the effectiveness of Shexiangbaoxinwang for the treatment of effort angina pectoris with 99m|TC-MIBI SPECT,” Shanghai Medicine, vol. 12, no. 12, pp. 24–25, 1996.
- C. Liu and P. Gong, “The effectiveness of Shengmai capsule for the treatment of stable angin,” Journal of Liaoning College of Traditional Chinese Medicine, vol. 5, no. 4, p. 263, 2003.
- J. Shen, Q. Yan, Z. Li, and Y. Zhang, “The medium and long-term outcomes of Danshen drop pill for angina pectoris,” Heilongjiang Medicine, vol. 6, no. 11, pp. 11–12, 2003.
- D. Yu, L. Jia, and Y. Yuan, “The effectiveness of Xuezhikang for angina and myocardial ischemia patients with normal cholesterol level,” Chinese Journal of Cardiovascular Rehabilitation Medicine, vol. 15, no. 2, pp. 181–184, 2006.
- Z. Hou, “The effectiveness of Danhong injection for the treatment of 123 patients diagnosed with stable angina,” Central Plains Medical Journal, vol. 34, no. 11, pp. 81–82, 2007.
- J. Yao, Y. Zhu, Y. Feng, and L. Yi, “The effectiveness of Aoweixin for treatment of famale amgina patients,” Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 5, no. 9, 2007.
- L. Gao, Y. Li, and K. Chen, “Effects of supplementing Qi and activating blood circulation method on plate let aggregation rate, adhesion rate and thromboxane B2 level in patients with atable angina P ector is and intolerable to aspirin,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 29, no. 7, p. 1081, 2008.
- H. Li, “The effectiveness of Dengzhanshengmai capsule for the prevention of recrudesce of stable angina in 100 patients,” Guangdong Medical Journal, vol. 29, no. 7, p. 1081, 2008.
- X. Ye, “The Combiantion of Xinyuan capsule and Simvastatin for the Secondary prevention of angina,” China Modern Medicine, vol. 16, no. 24, pp. 40–41, 2009.
- M. Z. Long, J. Wang, D. B. Wang, R. Chen, and M. Hong, “Clinical study on angina treated with Tong-Xin-Luo capsule,” Chinese Journal of Integrative Traditional and Western Medicine in Intensive and Critical Care, vol. 7, no. 5, pp. 270–272, 2000.
- Y. Wu and Z. Cui, “A 40 cases study of Shu-Xue-Tong for unstable angina,” Chinese Archives of Traditional Chinese Medicine, vol. 19, no. 5, 2001.
- G. M. Xiao, G. L. Yuan, X. Y. Liu, and Z. H. Shi, “Low dose of warfarin combined with Xue-Zhi-Kang for unstable angina,” The Journal of Practical Medicine, vol. 14, no. 4, pp. 270–271, 2001.
- B. Deng, “A 35 cases study of Zi-Ni-Guan-Xin-Tong-Tang for prevention and treatment of unstable angina,” Liaoning Journal of Traditional Chinese Medicine, vol. 29, no. 2, p. 90, 2002.
- G. Yang, “A 150 cases clinical obersvational study of Ru-Xin-An Capsual for unsatble angina,” Chinese Journal of the Practical Chinese With Modern Medicine, vol. 15, no. 6, p. 620, 2002.
- J. Zhao, “A clinical obervational study of Xue-Sai-Tong for unstable angina,” Journal of Qiqihar University of Medicine, vol. 23, no. 9, pp. 998–999, 2002.
- J. Gao, J. Sun, H. Su, and T. Xiao, “Clinical observation of unstable angnia treated by xintong oral solution,” Journal of Emergency in Traditional Chinese Medicine, vol. 12, no. 2, pp. 99–100, 2003.
- Y. Hong, P. Ren, and Y. Zhang, “Effects of Fufang Danshen Diwan on blood viscosity and serum-lipid of patient with unstable angina pectoris,” Modern Journal of Integrated Traditional Chinese and Western Medicine, vol. 12, no. 1, pp. 3–5, 2003.
- F. Nian, “Effect of Tongxinluo capsule on 30 unstable angina cases,” Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 1, no. 4, p. 244, 2003.
- Y. Zhang and Y. Hong, “Clinical research on patients with coronary heart disease treated by fuFang DanShen diwan,” Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine, vol. 3, no. 6, pp. 3–4, 2003.
- Y. Chen, “Clinical observation of Shexiang Baoxin pills for the treatment of spontaneous angina in coronary heart disease patients,” Journal of Emergency in Traditional Chinese Medicine, vol. 13, no. 12, pp. 797–798, 2004.
- Y. Chen, X. Tang, and L. Wang, “Effect of Acanthopanax as supplementary treatment for unstable angina patients,” People’s Military Surgeon, vol. 48, no. 7, pp. 378–380, 2005.
- J. Peng, “Clinical analysis of the 999 Shuxuening injection for the treatment of 46 patients with unstable angina,” Chinese Journal of the Practical Chinese with Modern Medical, vol. 18, no. 9, p. 1288, 2005.
- X. Liu and L. Wang, “Effect of Tongxinluo for the treatment of unstable angina,” Medical Journal of ChineSe People’S Health, vol. 18, no. 8, pp. 701–702, 2006.
- H. Yuan, Y. Hong, and X. Hu, “Effect of Shuxuening injection on TXB2 and 6-keto-PGF1ain senile unstable angina pectoris,” Medical Journal of the Chinese People’s Armed Police Forces, vol. 17, no. 10, pp. 746–748, 2006.
- H. Ning, F. K. Tang, N. W. Xi, L. Wong, and Q. Di, “Clinical study on therapeutic effect of tanshinone IIA sulfonic sodium combined with low molecular heparin against unstable angina,” Chinese Journal of Scientific and Technical Periodicals, vol. 18, pp. 195–198, 2007.
- J. H. Ma, W. P. Xiong, F. Wan, and M. Hua, “Study on treatment effect of tanshinone IIA sulfonic sodium combined with Xinkang on unstable angina,” China Modern Doctor, vol. 45, p. 97, 2007.
- S. M. Xiao, “Clinical observation on treatment with herbal formula Caihuxianxiong for unstable angina,” Chinese Journal of Integrated Medicine on Cardio/Cerebrovascular Disease, vol. 5, pp. 806–808, 2007.
- X. Z. Yang, Y. Q. Zhang, and H. L. Qian, “Clinical observation on tonifying deficiency and removing stasis therapy on elderly people with unstable angina,” Liao Ning Journal of Traditional Chinese Medicine, vol. 34, p. 605, 2007.
- M. S. Cai and Y. Q. Wei, “Study on danshen freeze-dried powder combined with low molecular heparin injection in treatment of unstable angina,” Internal Medicine of China, vol. 3, pp. 831–833, 2008.
- Y. Cai, “Clinical observation on therapeutic effect of puerarin on unstable angina,” Central Plains Medical Journal, vol. 35, p. 90, 2008.
- W. L. Chen and J. R. Fan, “Clinical Study of the formula with Soothing the liver reduce phlegm and absorb clots methods on patients with unstable angina pectoris,” Chinese Archives of Traditional Chinese Medicine, vol. 26, pp. 2209–2211, 2008.
- J. L. Liu, “Therapeutic effect of puerarin on angina,” China Medical Herald, vol. 5, pp. 102–103, 2008.
- Y. Zhang and G. Chen, “Influences of Tongxinluo on endothelin level and its efficacy in patients with unstable angina pectoris,” Chinese Medicine Modern Distance Education of China, vol. 6, no. 5, p. 441, 2008.
- Y. Cai and A. Wang, “Efficacy of integrated Chinese and western medicines for angina pectoris,” Modern Journal of Integrated Traditional Chinese and Western Medicine, vol. 18, no. 32, pp. 3959–3960, 2009.
- X. Chen and M. Ye, “Efficacy of Dengzhanshengmai Capsule for unstable angina pectoris,” Chinese Journal of Ethnomedicine and Ethnopharmacy, vol. 18, no. 22, p. 40, 2009.
- L. Su, B. Liu, X. Chen et al., “Danhong injection in treating 60 elderly patients with unstable angina,” Journal of Traditional Chinese Medicine, vol. 50, no. 3, p. 247, 2009.
- P. Wang, “Efficacy of Puerarin for unstable angina pectoris,” Chinese Journal of Misdiagnostics, vol. 9, no. 25, pp. 6123–6124, 2009.
- S. Wang, Y. Zhang, J. Yin, and D. Liu, “Efficacy of Shuxuetong injection for unstable angina pectoris,” Modern Journal of Integrated Traditional Chinese and Western Medicine, vol. 18, no. 19, pp. 2261–2262, 2009.
- N. Yu and L. Chen, “Efficacy of Tongxinluo in treating 68 patients with unstable angina pectoris,” China Modern Medicine, vol. 16, no. 13, pp. 104–105, 2009.
- Q.-Y. He, J. Wang, Y.-L. Zhang, Y.-L. Tang, F.-Y. Chu, and X.-J. Xiong, “Effect of Yiqi Yangyin decoction on the quality of life of patients with unstable angina pectoris,” Chinese Journal of Integrative Medicine, vol. 16, no. 1, pp. 13–18, 2010.
- Y. Wu and Q. Li, “Effect of Tongxinluo capsule on angina pectoris based on observation of 123 cases,” Journal of Handan Medical College, vol. 118, no. 2, pp. 114–115, 2005.
- Q. Li, Y. Wu, Q. Li, and H. Shi, “Observational study of the effect of Quyuningxin capsule on angina pectoris,” Journal of Emergency in Traditional Chinese Medicine, vol. 17, no. 12, pp. 1658–1659, 2008.
- M. Dong, “Effect of combined Shexiangbaoxin pill and isosorbide dinitrate on coronary heart disease,” Guangming Journal of Chinese Medicine, vol. 23, no. 12, pp. 1985–1986, 2008.
- H. Shi and Q. Shi, “Influence of compound Danshen Dropping pill on total ischemia burden and heart rate variability in Angina pectoris of coronary disease,” Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 7, no. 6, pp. 649–651, 2009.
- K. Shi and Y. Jiang, “Clinical study on the therapeutic effect and safety of combined atorvastatin and tongxinluo capsule in treating patients with coronary heart disease,” Journal of Sichuan of Traditional Chinese Medicine, vol. 27, no. 4, pp. 61–63, 2009.
- M. Lin and J. Wu, “Clinical analysis of Compound Danshen Drop pill in the treatment of 78 cases of senile coronary artery disease angina,” China Medical Herald, vol. 7, no. 7, pp. 52–53, 2010.
- J. Luo and H. Xu, “Outcome measures of chinese herbal medicine for coronary heart disease: an overview of systematic reviews,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 927392, 2012.
- K. J. Li, “A systematic review on randomized controlled trials for treatment of unstable angina pectoris with Danshen preparation,” Guangming Journal of Chinese Medicine, vol. 22, no. 2, pp. 37–40, 2008.
- K. J. Li, “A systematic review on randomized controlled trials for treatment of stable angina pectoris with Danshen preparations,” Herald of Medicine, vol. 26, no. 4, pp. 383–386, 2007.
- W. Cao, D. Lan, T. Zhang, C. Tang, T.-X. Wu, and G.-J. Liu, “Effect of Dengzhanhua Injection for angina pectoris: a systematic review,” Chinese Journal of Evidence-Based Medicine, vol. 5, no. 4, pp. 317–322, 2005.
- Y.-L. Jia, S.-K. Zhang, F.-F. Bao, F.-Y. Huang, and S.-W. Leung, “Indirect comparison of tongxinluo capsule and danshen dripping pill for angina pectoris: a systematic review,” Chinese Journal of Evidence-Based Medicine, vol. 11, no. 8, pp. 919–931, 2011.
- T. Wu, R. A. Harrison, X. Chen et al., “Tongxinluo (Tong xin luo or Tong-xin-luo) capsule for unstable angina pectoris,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD004474, 2006.
- X. Y. Li, F. Du, W. L. Cheng, and H. Xia, “Systematic review on randomized controlled trials for treatment of unstable angina pectoris by Shuxuetong,” Modern Journal of Integrated Traditional Chinese and Western Medicine, vol. 19, no. 18, pp. 2231–2233, 2010.
- Y. Zha and L. Li, “Systematic evaluation of yinxing dam injection in the treatment of angina pectoris,” China Pharmacy, vol. 21, no. 44, pp. 4143–4147, 2010.
- W. Zhao, J. S. Xiang, and K. Ye, “Systematic review on randomized controlled trials for treatment of UAP by Ginkgo extract,” Journal of Liaoning University of Traditional Chinese Medicine Pharmacology and Clinical Practice, vol. 12, no. 11, pp. 216–220, 2010.
- J. H. Zhang, H. C. Shang, X. M. Gao et al., “Compound salvia droplet pill, a traditional Chinese medicine, for the treatment of unstable angina pectoris: a systematic review,” Medical Science Monitor, vol. 14, no. 1, pp. RA1–RA7, 2008.
- S. Y. Jiang, J. C. Tong, R. Y. Shun, and H. T. Xie, “Meta-analysis of compound salvia pellet for coronary angina pectoris,” Practical Pharmacy and Clinical Remedies, vol. 10, no. 6, pp. 334–337, 2007.
- G. H. Guyatt, A. D. Oxman, G. E. Vist et al., “GRADE: an emerging consensus on rating quality of evidence and strength of recommendations,” British Medical Journal, vol. 336, no. 7650, pp. 924–926, 2008.
Copyright © 2013 Chen Mao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.